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Abstract
A structural rationale for recent emergence of azole (imidazole and triazole) resistance associated with CYP51 mutations in
the wheat pathogen Mycosphaerella graminicola is presented, attained by homology modelling of the wild type protein and
13 variant proteins. The novel molecular models of M. graminicola CYP51 are based on multiple homologues, individually
identified for each variant, rather than using a single structural scaffold, providing a robust structure-function rationale for
the binding of azoles, including important fungal specific regions for which no structural information is available. The wild
type binding pocket reveals specific residues in close proximity to the bound azole molecules that are subject to alteration
in the variants. This implicates azole ligands as important agents exerting selection on specific regions bordering the pocket,
that become the focus of genetic mutation events, leading to reduced sensitivity to that group of related compounds.
Collectively, the models account for several observed functional effects of specific alterations, including loss of triadimenol
sensitivity in the Y137F variant, lower sensitivity to tebuconazole of I381V variants and increased resistance to prochloraz of
V136A variants. Deletion of Y459 and G460, which brings about removal of that entire section of beta turn from the vicinity
of the binding pocket, confers resistance to tebuconazole and epoxiconazole, but sensitivity to prochloraz in variants
carrying a combination of A379G I381V DY459/G460. Measurements of binding pocket volume proved useful in assessment
of scope for general resistance to azoles by virtue of their accommodation without bonding interaction, particularly when
combined with analysis of change in positions of key amino acids. It is possible to predict the likely binding orientation of an
azole molecule in any of the variant CYPs, providing potential for an in silico screening system and reliable predictive
approach to assess the probability of particular variants exhibiting resistance to particular azole fungicides.
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Introduction
Mycosphaerella graminicola causes Septoria leaf blotch, the primary
foliar disease of winter wheat in most western European countries
[1]. Control of the pathogen now relies on the application of azole
fungicides which are demethylase inhibitors (DMIs) that inhibit
CYP51 activity. CYP51 is a cytochrome P450 that catalyses the
oxidative removal of the 14a-methyl group of lanosterol or
eburicol in yeasts and fungi - an essential step in the production of
sterols. Azoles bind as the sixth ligand to the haem in CYP51 via
the unprotonated N atom thus occupying the active site and acting
as non-competitive inhibitors [2].
Many different amino acid alterations (substitutions and
deletions) have been associated with azole resistance in the
MgCYP51 protein of western European M. graminicola popula-
tions [3,4,5,6,7]. Similarly, mutations corresponding to azole
resistance have also been identified in other fungal CYP51s,
including the opportunistic human pathogens Candida albicans [8]
and Aspergillus fumigatus [9]. In M. graminicola CYP51 substitutions
include Y137F which confers resistance to triadimenol [6], I381V
which confers resistance to tebuconazole [4] and V136A that
confers resistance to prochloraz [6]. Of particular interest is a
deletion of two amino acids Y459/G460 seen in many recent
populations [7], located in a fungal specific region of CYP51.
This deletion and other single amino acid substitutions of residues
459–461 are frequently found in populations exhibiting increased
resistance to azole compounds, and a large number of multiple
alterations have arisen in M. graminicola CYP51 [6,7]. Such
multiple changes have previously been identified in azole resistant
Candida albicans [10], but not on the same scale. It is likely such
multiple alterations have occurred in M. graminicola CYP51 by
point mutation, intragenic recombination [5] and selection by
successive treatments over time with different azoles and azole
mixtures. In addition it has been suggested that ascospores have
been spread with the prevailing wind (from west to east) over
Europe [7]. This has resulted in replacement of wild type isolates
in current European populations by a series of more complex
CYP51 variants, the most prevalent in the UK M. graminicola
population now being L50S S188N A379G I381V DY459/G460
N513K [7].
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20973Although no fungal CYP51 has been crystallised to date,
homology models based on the crystal structure of soluble CYP51
from Mycobacterium tuberculosis [11] have been proposed. Prior
to the elucidation of this structure, the CYP51 of C. albicans
was modelled by molecular dynamics based on the structure of
Pseudomonas putida P450cam [12], and this model was used to
rationalise the differential inhibition with azoles [13].
In recent years, the Cytochrome P450 enzymes of a number of
species have been crystallised, with over 350 structures deposited
on the PDB by mid 2010, providing a basis for the first time for
reliable multi-homologue modelling of wild type and mutant
CYP51 structures. This should provide an insightful approach for
assessing the relative structural impact of single and multiple
alterations on the likely effects on azole binding in CYP51s.
Successful amino acid alterations may exert an effect in one of
several ways that could lead to target protein mediated resistance to
a given group of chemical compounds. Azole resistance may occur
dueto alterations that invokea conformational change that removes
a specific residue (or residues) away from interaction with an azole.
Alternatively, a key residue may be directly substituted. Either of
these can result in the azole not being accommodated normally
within the active site with regard to the coordinating haem (this may
include occlusion of the azole from the active site) or may lead to a
lower azole binding affinity due to changes in interaction with
surrounding residues. Multiple alterations, of course, may result in
higher or cross-resistance to azoles through a cumulative effect or
they may be compensatory, restoring or improving CYP51 function
which may otherwise reduce the fitness of the variant strain. It is
likely that the scope for changing the gross architecture of the haem
pocket is constrained by the evolutionary requirement of the
molecule to maintain its native functions.
We have modelled alterations individually and in combination
and simulated the docking of four azoles, epoxiconazole, tebuco-
nazole, triadimenol and prochloraz. We discuss our models with
respect to the changes commonly seen in the field and the selection
pressures that are likely to have brought about these alterations. We
present a structural rationale for resistance associated with CYP51
changes in M. graminicola. With our modelling approach, it is
possible to assess the likely binding of any azole in any of the variant
proteins, providing the potential for an in silico screening system for
azole binding in fungal CYPs. Although other mechanisms of
resistance to azoles may contribute to the overall phenotype
(overexpression of CYP51 and upregulation of efflux transporters)
[14], the affinity of an azole for a CYP51 variant is fundamental to
its functioning as an inhibitor, and new alterations and combina-
tions of alterations in CYP51 associated with azole resistance
continue to emerge [15]. Therefore molecular modelling will
provide insights into azole binding in M. graminicola CYP51 and will
aid in the design of new inhibitors and possibly the prediction of the
likely resistance phenotype of a strain. It may also be possible to
predict likely alterations which may occur as a result of azole
treatment in the future. Furthermore the information generated in
M. graminicola CYP51 models may be applicable to other fungal
CYP51s resistant to azoles. The results presented here provide
evidence of a robust protein model which may now be used to
informand predictfutureresistancein the field whichwill be further
confirmed by laboratory tests.
Methods
Homology Modelling
Structural modelling of wild type and 13 mutant Myco-
sphaerella graminicola CYP51 (MgCYP51) sequences was carried
out using an automated homology modelling pipeline built with
the Biskit structural bioinformatics platform [16], which scans the
entire PDB for candidate homologies. This work was based on the
PDB as compiled on 15 February, 2010, at which time there were
316 CYP structures available. The wild type sequence used is of
strain IPO323. The genome sequence of this strain is now
publically available (http://genome.jgi-psf.org/Mycgr3/Mycgr3.
home.html). The naturally occurring alterations were subsequently
manually incorporated into the wild type sequence. The pipeline
workflow incorporates the NCBI tools platform [17], including the
BLAST program [18] for similarity searching of sequence
databases. T-COFFEE [19] was used for alignment of the test
sequence with the template. Homology models were generated
over 10 iterations of the MODELLER program [20]. All models
were visualized using the molecular graphics program Chimera
[21]. CYP homologues are selected by the pipeline as those with
the highest identity to the test sequence. Rather than simply
replacing the candidate amino acid(s) in a model of wild type
MgCYP51 each sequence is modelled separately. Therefore each
of the MgCYP51 variants may be modelled on a different selection
of homologues (table 1) depending on the identity shared with
available CYP structures resulting in a model which reflects the
global structural differences that result from amino acid alter-
ations. Root mean square deviation (RMSD) of models compared
to wild type were calculated using Chimera [21] to attain a
measure of global structural change, and residues within given
distance ranges of the docked azoles were identified using the zone
function in the same program.
Measurement of binding pocket volume
The volume of the haem cavity of the wild type and variant
protein models was determined using Pocket-Finder written
by Alasdair Laurie and Richard Jackson, University of Leeds,
UK, (http://www.modelling.leeds.ac.uk/pocketfinder/) which is a
pocket detection algorithm based on Ligsite [22].
Azole docking
The azole molecules (triadimenol, tebuconazole, epoxiconazole
and prochloraz) were docked by superimposition within the active
site cysteine pocket, with the unprotonated N atom coordinated by
the haem iron atom. The entire azole ring proximal to the haem
group was precisely positioned according to the haem position and
fluconazole binding in PDB structure 3L4D (deposited December
2009), the crystal structure of sterol 14a demethylase from
Leishmania infantum (Lepesheva et al., to be published). We selected
the CYP51 structure from Leishmania infantum (Lepesheva et al., to
be published) as the template for azole docking on the basis of it
possessing the highest identity with M. graminicola CYP51 of any of
the structures co-crystallised with an azole molecule. The variant
protein structures were also placed by superimposition and
screened for conflicts with docked azoles at a required separation
threshold of 0.6 A ˚. Residues within given distance ranges (,3.0 A ˚,
3.0–3.5 A ˚, 3.5–4.5 A ˚) of the docked azoles were identified using
the surface zone function in the Chimera molecular graphics
program and H-bonds were predicted [21].
M. graminicola isolate azole sensitivity testing
Sensitivity assays were modified from Fraaije et al. (2007) [4]. A
100 ml aliquot of 26 Sabouraud Dextrose Liquid Medium
(SDLM; Oxoid, Basingstoke, UK) amended with decreasing
concentrations of epoxiconazole (75, 20, 5.3, 1.4, 0.38, 0.101,
0.027, 0.007, 0.002, 5.00E-04 and 1.36E-04 mg l
21), tebucona-
zole (75, 27, 9.9, 3.6, 1.3, 0.48, 0.17, 0.063, 0.023, 0.008 and
0.003 mg l
21), triadimenol (75, 25, 8.3, 2.8, 0.93, 0.31, 0.10,
0.034, 0.011 and 0.004 mg l
21) and prochloraz (15, 3.0, 0.60,
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1.54E-06 mg l
21) was added to wells of flat-bottomed microtitre
plates (TPP 92696 test plates, Trasadingen, Switzerland). After 7
days growth at 15uC on YPD to ensure yeast-like growth, isolates
were suspended in 5 ml of sterile distilled water. Aliquots of 100 ml
of isolate spore suspensions (2.5610
4 spores ml
21) were added to
each well. Plates were incubated for 3 days at 23uC, and growth
measured by absorbance at 630 nm using a FLUOstar OPTIMA
microplate reader (BMG Labtech GmbH, Offenberg, Germany).
Fungicide sensitivities were determined as 50% effective concen-
tration (EC50) using a dose response relationship according to the
BMG Labtech Optima Software. Resistance factor (RF) of each
isolate was calculated as fold change in EC50 compared to wild-
type isolates.
Results and Discussion
Wild type MgCYP51 and a selection of MgCYP51 variants were
modelled. Amino acid alterations currently observed in the field
were modelled in order to elucidate the contribution of single and
multiple alterations on the resistance and activity profile of
MgCYP51. We used the PocketFinder (http://www.modelling.
leeds.ac.uk/pocketfinder/) algorithm to calculate the predicted size
of the pocket volumes of our 14 models and the root mean squared
deviation (RMSD) as a measure of the overall change in the
conformation of our models compared to the wild type model.
Together these give a measurement of the effect an alteration or
combination of alterations is likely to cause on the structure of
MgCYP51 (table 2). In addition, we have used molecular modelling
to simulate the docking of epoxiconazole, prochloraz, tebuconazole
and triadimenol in wild type and mutant models to gain an insight
into the mechanism behind the associated azole resistance. We have
considered the effect that individual alterations may contribute and
the overall profiles expected in variants carrying multiple changes
currently observed in the field.
Wild type M. graminicola CYP51
M. graminicola CYP51 is predicted to possess a typical P450 fold
with the generally conserved structural core formed by helices E, I,
J, K, and L around the haem prosthetic group (figure 1), similar to
the recently characterised human CYP51 [23], and the access to
the haem cavity guarded by the loop between helices B and C.
The predicted volume of the wild type protein is 1685 A ˚ 3,
including the space occupied by the haem. A total of 86 residues
were identified as lining the pocket of the wild type protein (text
S1), including 5 residues (V136 (on the B–C loop), I381 (K–L
loop), Y459, G460 and Y461) observed as sites of alteration
leading to azole resistance in M. graminicola [24]. Figure 1 shows
the location in the wild type protein structure of the residues
subject to alteration. V136 and Y137 reside on the access channel
end of the binding pocket, while I381, Y459, G460 and Y461 are
at the haem end. L50 and A379 do not directly border the binding
pocket, but form part of secondary structures that are immediately
adjacent to the cavity. S188 and N513 are highly exposed on the
outside of the protein, far removed from the binding regions.
The numbers of residues bordering the binding pocket
and predicted to be within 3 A ˚ of epoxiconazole, prochloraz,
tebuconazole and triadimenol are shown in table 2 (the residues
predicted to be within 3.0–3.5 A ˚ and 3.5–4.5 A ˚ of docked azoles
are listed in table S1). The docking of azoles to the wild type
MgCYP51 reveals a pattern of residues immediately proximal to
the azole docking site known to be subject to mutation which
results in azole resistance (V136, Y137, I381, Y459, G460, and
Y461). All these residues are implicated, for instance, by the
interactions of triadimenol docking (closer than 4.5 A ˚). By this
analysis, L50, S188, A379 and N513 are confirmed to be located
away from the binding region. This modelling is consistent with
the use of azoles leading to the emergence of the key resistance
mutations at Y137, I381V and Y459.
Impact of alterations
The effect of individual alterations upon CYP51 structure was
assessed by modelling the altered forms of the protein. Test
sequences were modified accordingly and input into the modelling
pipeline. Table 1 details the changes in homologues adopted by
the automated modelling pipeline and changes in sequence
homology, which lead to the structural changes observed in the
modelled structures. The proximity of residues to each of the
Table 1. Modelled M. graminicola CYP51 mutants, homologues adopted by the automated modelling pipeline and the highest
percentage homology achieved.
Variant % Homology PDB Homologues
Wild type (wt) 33.6 3DBG 3G1Q 2CIB 3I3K 3GW9 3L4D
L50S 34.5 3DBG 3G1Q 2CIB 3I3K 3GW9 3L4D
Y137F 33.3 3DBG 3G1Q 2CIB 3I3K 3GW9 3L4D
Y459D 34.2 3DBG 3G1Q 2CIB 3I3K 2VE3 3GW9 3L4D
G460D 33.3 3DBG 2Q9F 3G1Q 2CIB 3I3K 2VE3 3GW9 3L4D
L50S Y461H 32.7 3DBG 2Q9F 3G1Q 2CIB 3I3K 2VE3 3GW9 3L4D
L50S Y461S 32.7 3DBG 2Q9F 3G1Q 2CIB 3I3K 2VE3 3GW9 3L4D
L50S I381V Y461H 33.1 3DBG 3G1Q 2CIB 3I3K 2VE3 3GW9 3L4D
L50S V136A Y461H 33.1 3DBG 2Q9F 3G1Q 2CIB 3I3K 2VE3 3GW9 3L4D
L50S S188N N513K 34.2 3DBG 3G1Q 2CIB 3I3K 3GW9 3L4D
L50S S188N DY459/G460 N513K 29.1 3DBG 2CD8 2Q9F 3G1Q 2CIB 3I3K 3GW9 3L4D
L50S S188N I381V DY459/G460 N513K 33.1 3DBG 3G1Q 2CIB 3I3K 3GW9 3L4D
L50S V136A S188N DY459/G460 N513K 29.3 3DBG 2CD8 2Q9F 3G1Q 2CIB 3I3K 3GW9 3L4D
L50S S188N A379G I381V DY459/G460 N513K 33.6 3DBG 3G1Q 2CIB 3I3K 3GW9 3L4D
doi:10.1371/journal.pone.0020973.t001
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compared with the wild type protein.
For the purpose of discussion of the impacts of alterations, the
variants are divided into three groups; i) Alterations that do not
affect azole binding, ii) Alterations affecting the size and
accessibility of the binding pocket, iii) Alterations affecting the
localisation of residues interacting with azoles.
i) Alterations that do not affect azole binding
L50S. The inclusion of L50S on its own causes only a slight
increase in cavity volume (table 2). The L50S substitution appears
in the majority of subsequent combinations of multiple mutations
and its location away from the cysteine pocket (L/S50 is not within
4.5 A ˚ of any of the docked azoles in any of our 14 models (table
S1) and its marginal impact on protein conformation indicate that
it may indeed represent a natural variant in its own right which is
not associated with azole resistance. The L50S alteration also does
not affect activity as shown by expression in yeast [25].
L50S S188N N513K. L50S S188N N513K is a natural
variant found in wild type populations in New Zealand sensitive to
all azoles (Cools et al., unpublished). Although the model shows a
significant increase in the volume of the haem cavity (table 2), and
generally fewer residues in close proximity to the azoles, key
residues for interaction, namely Y137 and I381 are as close or
closer to the docked azoles than in the wild type protein (table S1),
being within 3.5 A ˚ of all azoles, an arrangement consistent with
general azole sensitivity. V136 is within 4.5 A ˚ of triadimenol,
tebuconazole and epoxiconazole, but not prochloraz, also like the
wild type protein.
Leroux et al., (2007) have suggested that the mutations recorded
at positions 50, 188, 379 and 513 do not seem to be related to
DMI resistance, but suggest that M. graminicola populations might
be constituted of two independent entities that represent sympatric
species [6]. They suggest that S188N and N513K (along with
L50S) are always seen together and may have originated from the
same haplotype rather than having been selected through
conferring azole resistance [6]. Brunner et al [5] have proposed
an alternative hypothesis, that rapid evolution of the CYP51 gene
has led to two distinct populations of molecules, one based on the
accumulation of a series of point mutations within the ancestral
wild-type template and another that is highly diverged as a result
of a few intragenic recombination events that brought together the
different point mutations from different regions of the gene.
This genotype may exhibit general sensitivity to the above
azoles and might present an increased selective pressure for
mutation at the 136 and 381 positions. This is supported by the
observation that the L50S variant model brings I381 into closer
interaction with triadimenol (from within 4.5 to ,3.0 A ˚),
tebuconazole and epoxiconazole (now within 4.5 A ˚) and remains
within 3.0 A ˚ of prochloraz (table S1). There is a reduction in the
overall number of residues within 4.5 A ˚ of triadimenol (13 to 9)
and prochloraz (11 to 10), but an increase in those within 4.5 A ˚ of
tebuconazole (12 to 14). There are also more polar residues within
4.5 A ˚ of tebuconazole and epoxiconazole (table 2).
ii) Alterations affecting the size and accessibility of the
binding pocket
The predicted structure of the L50S I381V Y461H variant
displays a notable constriction of the binding pocket, while the
cavity of L50S S188N N513K is more than double the size of the
wild type pocket, suggesting that the slight increase in cavity volume
brought about by L50S on its own is modified considerably by the
other alterations with which it is combined.
Variants including I381V
Several of the multiple alterations modelled are seen in current
populations. The structural models will be discussed in relation to
the resistance profiles observed and compared to wild type
structure to account for resistance, beginning with those that
include the influential I381V alteration.
Table 2. Binding pocket volumes of modelled M. graminicola CYP51 mutants, and their RMSD values compared to wild type,
ordered according to cavity volume.
Variant
Volume
(A ˚ 3) RMSD
No. residues within
3A ˚ of azole
No. polar residues
within 4.5 A ˚ of azole
EPTT r i EPTT r i
L50S I381V Y461H 1 2 1 7 0 . 9 5 4 7666 4444
L50S Y461S 1 4 6 0 1 . 0 1 8 5653 3242
wild type (wt) 1 6 8 5 - - - 6564 3344
L50S V136A Y461H 1 9 7 1 1 . 0 4 4 8668 5455
Y459D 2 2 6 3 0 . 9 6 2 6544 1333
L50S 2 2 6 9 1 . 0 7 6 4444 4364
L50S Y461H 3 4 5 1 0 . 9 7 1 5434 4553
G460D 3 5 0 1 0 . 9 5 8 6675 2333
L50S S188N N513K 3 7 5 4 0 . 9 0 5 2232 2331
Y137F 3 7 6 9 0 . 7 9 8 3342 2333
L50S V136A S188N DY459/G460 N513K 4 3 5 5 1 . 0 5 1 3441 0111
L50S S188N A379G I381V DY459/G460 N513K 5 0 6 0 0 . 9 1 2 4322 1021
L50S S188N I381V DY459/G460 N513K 5 2 0 4 0 . 9 9 8 4431 1111
L50S S188N DY459/G460 N513K 5 7 2 5 0 . 9 8 3 3332 1231
Wild type shaded, variants that occur in the field shown in bold.
doi:10.1371/journal.pone.0020973.t002
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prochloraz. L50S I381V Y461H is a common natural variant,
which causes resistance to epoxiconazole and slightly decreased
sensitivity to prochloraz (table 3). The predicted cavity volume of
this mutant protein model is notably smaller than wild type at
1217 A ˚ 3 and therefore the number of residues within interaction
range of docked azoles is increased (table 2).
It is the incorporation of I381V that causes the decrease in the
cavity volume. The single I381V substitution reduces the cavity
volume to 1438 A ˚ 3, and similarly causes a relative decrease in the
cavity volume in other mutants where it appears (table 2).
Interestingly, L50S I381V and I381V have never been observed in
populations in isolation, and do not complement CYP51 function
in a heterologous system [25], indicating that the conformational
change also results in decreased activity. Leroux and colleagues
have observed high resistance of this laboratory variant to
triadimenol, tebuconazole and epoxiconazole [6].
I381V is usually found in populations with changes in the 459–
461 region [6,7], indicating that CYP51 function is lost with
I381V and this mutation is only selected after other alterations
have occurred. Indeed, it has been proposed that a recombination
event brought these two mutations together [5]. It has also been
shown in the heterologous system that the combination of I381V
and Y459–Y461 rescues the lethality of I381V alone [25].
I381/V381 is within 4.5 A ˚ of docked azoles in 36 of our 56
docking simulation models (table S2) and so is clearly under
substantial evolutionary pressure. The I381V substitution results in
the entire 459–461 section and Y137 being worked closer to the
docked azole (table 2, table S1) – substantial structural changes which
may account for the lack of CYP51 activity seen and a consequent
lack of selective pressure without the presence of other mutations.
L50S I381V Y461H is a common variant, resistant to
tebuconazole and sensitive to prochloraz. No strict pattern of
individual residues within interaction range of docked azoles can
account for resistance, in fact Y137 is brought to within 3 A ˚ of all
azoles including prochloraz and the proximity of V136 with
triadimenol, tebuconazole and epoxiconazole is maintained. It may
be that the substitution of tyrosine by histidine at position 461 in
itself may cause azole resistance, though this alone does not explain
why L50S I381V Y461H causes further decreases in sensitivity to
tebuconazole and epoxiconazole compared to L50S Y461H.
Proximity to V381, G460 and S315 also appears to be related to
observed resistance. All are out of range of tebuconazole, while
V381 is within 3 A ˚ and G460 is within 3.5 A ˚ of prochloraz. Thisfits
in with the observed EC50 and resistance factor values (table 3),
which are markedly higher for tebuconazole than for prochloraz.
Therefore, here it appears that it is the general constriction of
the cavity combined with removal of structure at the 460–461 end
that may be responsible for the observed resistance to tebucona-
zole and epoxiconazole, while prochloraz gives a different profile,
lying closely to V381 and G460. This protein also conferred
impaired growth in a heterologous system [25], indicating that the
conformational change also results in decreased activity.
Our modelling suggests that the main effect of the I381V
alteration appears to have been to reduce the interactions of
triadimenol, tebuconazole and epoxiconazole by constriction of
the haem cavity at the K and L helix end, and subsequent removal
from interaction range of key tyrosine and polar residues elsewhere
around the cavity, rather than removal of the 381 position itself. In
the wild type model, I381 is within 3 A ˚ of prochloraz and within
4.5 A ˚ of triadimenol, but out of range of epoxiconazole and
tebuconazole. In the L50S model, I381 is generally around 1.5 A ˚
closer to the docked azoles, being within 3 A ˚ of prochloraz and
triadimenol and within 4.5 A ˚ of epoxiconazole and tebuconazole
(table S1). I381V has not been observed in the field without L50S.
Even following multiple alterations including I381V, the 381
position remains in close range of prochloraz, though not the other
azoles, which appears to be the strongest factor in the retention of
sensitivity to prochloraz.
The DY459/G460 deletion
Alterations of residues 459 and 460 of MgCYP51 occur
frequently. Docking of azoles in our models reveals these residues
are within 4.5 A ˚ in 34 of the 40 docking models that do not
include the DY459/G460 deletion, indicating that these amino
acids are important in azole binding. The residues 459–461 lie
within a region (438–463) which is specific to fungal CYP51s. It is
this region which renders fungal models of MgCYP51 that use
only a single homologue as a template unreliable. Can ˜as-Gutie ´rrez
et al. used the Myocbacterium tuberculosis CYP51 structure as a
template for an M. fijiensis model and found the area between
position 442–472 (their alignment) resulted in an energetic
difference between the model and the scaffold [26]. In contrast,
our method is not constrained to a single homologue and our
results below show how important this region is in relation to azole
resistance, particularly in the DY459/G460 mutant. Indeed, this is
the first fungal CYP51 model that provides structural evidence for
the importance of Y459–Y461 for azole binding.
The incorporation of the Y459/G460 deletion is consistently
associated with large increases in cavity volume. A deletion at
Figure 1. Wild type CYP51. Wild type CYP51 binding triadimenol,
showing the location in the wild type protein structure of the residues
subject to alteration; I381 and Y137 labelled, V136, in grey,
neighbouring Y137, triadimenol in orange and the Y459/G460 region
in yellow. The chloride group (green) of triadimenol is predicted to form
a weak hydrogen bond with Y137. The I helix of the protein is shown
running down the left hand side of the bound azole and the K helix
behind I381 extending down behind the haem group. Figure 1 shows
the location in the wild type protein structure of the residues subject to
alteration. L50 and A379 do not directly border the binding pocket, but
form part of secondary structures that are immediately adjacent to the
cavity. S188 and N513 are located on the outside of the protein, far
removed from the binding regions.
doi:10.1371/journal.pone.0020973.g001
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and in combination with other mutations also increases the cavity
volume (L50S S188N DY459/G460 N513K (5725 A ˚3) compared
to L50S S188N N513K (3754 A ˚3). This increase in volume is to
be expected, as the deletion results in the removal of that whole
section of beta turn from the vicinity of the haem pocket
(figure 2A). The removal of this region out of the haem cavity to
the outside of the protein is a feature of all mutants carrying the
DY459/G460. Variants carrying the deletion also display some of
the highest RMSD values compared to wild type.
DY459/G460 consequently brings about a dramatic effect on
the proximity of key residues to each of the azoles docked. Y137,
Y461, and of course the deleted Y459 and G460, are entirely
removed from the binding pocket whilst the lysine residues K133,
K148 and K149 move into the pocket (figure 2A). These changes
are brought about by gross rearrangement of the two sections
involved, namely that containing K133, Y137, K148 and K149
and the beta turn section 450–470 containing residues 459–461
(figure 2A). In B. graminis f. sp. hordei the combination of the Y136F
and K147Q substitution displays additive effects towards triadi-
menol resistance [27].
The loss of interaction with Y137 and Y459 balanced by the
introduction of the two lysine residues within range for interaction
is in good keeping with the observation of medium level resistance
to all the azoles tested [6]. Interestingly this alteration has been
predicted to have arisen in two individual events by Brunner et al.
[5], further demonstrating the importance of this deletion in the
development of higher level azole resistance. This is the first model
to show the considerable effect of deletion of 459/460.
L50S S188N DY459/G460 N513K and L50S S188N I381V
DY459/G460 N513K
The largest change in pocket volume was found in the natural
variant L50S S188N DY459/G460 N513K (5724 A ˚ 3). All the
Figure 2. Azole docking in mutant proteins. (A) The effect of the Y459/G460 deletion, shown with tebuconazole docked. Y137 is out of range of
interaction, while K133 and K148 are introduced to the pocket and are in close range of the azole. (B) Simulated docking of triadimenol in the Y137F
mutant protein, showing the spatial conflicts with F137 and to a lesser extent, I381, suggesting that triadimenol binding would be significantly
impaired. Triadimenol is shown in stick representation, surrounded by the external atomic surface in light orange. V136, F137 and I381 are labelled,
and the 459–460 region in yellow. The reactive chloride group (green) of triadimenol is in spatial conflict with F137. (C) Resistance to prochloraz and
sensitivity to tebuconazole of the L50S V136A S188N DY459/G460 N513K variant, showing tebuconazole (by element) and prochloraz (purple)
superimposed, K148 (by element, below) out of range of prochloraz but within range of tebuconazole and Y137 (below) removed from interaction
range. (D) Figure 2D. Resistance to tebuconazole and sensitivity to prochloraz of the L50S S188N A379G I381V DY459/G460 N513K variant, showing
tebuconazole (by element) and prochloraz (purple) superimposed in docked position, V381 (grey) out of range of tebuconazole but within range of
prochloraz and the hydroxyl groups of Y123 and Y137 (left) again closer to prochloraz.
doi:10.1371/journal.pone.0020973.g002
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except for I381 which remains within 3.5 A ˚ and 3 A ˚ of
triadimenol and prochloraz respectively. Q313 is brought within
range of tebuconazole, and H314 within reach of all the azoles.
Y123 is within 3 A ˚ of triadimenol, tebuconazole and epoxicona-
zole and within 4.5 A ˚ of prochloraz. This variant demonstrates
substantial resistance to epoxiconazole and tebuconazole and
more modest resistance to prochloraz (table 3), which suggests that
proximity to I381 is a factor in determining the extent of resistance
to a given azole, but particularly prochloraz.
For the natural variant, L50S S188N I381V DY459/G460
N513K, the model showed the haem cavity volume increased to
5204 A ˚ 3 and other than V381 (within 3.5 A ˚ of triadimenol and
prochloraz), all mutated residues are removed from the binding
pocket. However Y123 is within 3 A ˚ of all azoles - this is the only
polar residue found in interaction range of all docked azoles.
Isolates carrying this variant are resistant to tebuconazole and
sensitive to prochloraz [4], our models suggesting again that the
proximity of the 381 position to prochloraz is the determining
factor in the differential sensitivities observed.
L50S S188N DY459/G460 N513K and L50S S188N I381V
DY459/G460 N513K may reduce sensitivity to some azoles in a
similar way since Y137 and lysine residues (K133, K148 and
K149) are all more than 4.5 A ˚ from docked azoles.
iii) Alterations affecting the localisation of residues
interacting with azoles
Y137F. The Y137F substitution brings about a substantial
increase in the size of the pocket to over twice that of the wild type
(3769 A ˚ 3, table 2). This is the largest change in cavity volume
brought about by any of the single alterations modelled. However,
Y137F does not exert its effect by reducing the number of polar
residues in proximity to the bound azoles (table 2) and it also does
not remove the altered residue from the pocket. In the model F137
is closer to the docked azoles than Y137 (within 4.5 A ˚ of all azoles
and within ,3A ˚ of triadimenol, table S1) and is pushed into an
obstructive position prohibiting the binding of triadimenol
(figure 2B). The docking of the other azoles within the haem
cavity is not constrained by the occlusion of the pocket around the
137 position; rather it is the loss of the hydroxyl group incurred by
the substitution of tyrosine with phenylalanine which may result in
the minor decrease in sensitivity to tebuconazole, epoxiconazole
and prochloraz observed. The conformational change caused by
the substitution also serves to take Y459 away (around 2 A ˚) from
the azole binding position. Y459 is within 3 A ˚ of all docked azoles
in the wild type, but in the mutant is only within 4.5 A ˚ of
triadimenol and is moved out of interaction range (.4.5 A ˚)o f
tebuconazole, epoxiconazole and prochloraz (table S1).
These modelling observations are consistent with resistance
recorded in M. graminicola and other fungi with mutations of
equivalent residues. The mutations Y132H in Candida albicans
[28], Y136F in M. fijiensis [26], Y136F in Erysiphe gramainis f.sp.
hordei [29] and Y136F in Uncinula necator [30] and have all been
associated with azole resistance. Y137F in M. graminicola is
specifically associated with triadimenol resistance [6]. Strains
carrying the Y137F substitution are believed to have emerged
due to triadimenol usage [24] and although the mutation was
common in the early 1990s it is now rare in most European
populations [7], having been replaced by mutations in the 459–
461 region. In addition the large conformational change
predicted by our model is further supported by the fact that the
activity of MgCYP51 Y137F is greatly reduced, to around 10% of
that of the wild type [31].
Y459D, G460D, Y461H and Y461S alterations
Although single substitutions at positions 459, 460 and 461 all
lead to an increase in cavity volume to varying extents (table 2),
indeed G460D leads to a more than doubling of the cavity volume
(to 3501 A ˚ 3), the main effects of these single substitutions are with
regard to the localisation of azole-interacting residues.
With the addition of the substitution Y459C in L50S Y459C, a
rare variant, Y137 is withdrawn from the pocket (.4.5 A ˚ from all
docked azoles)while I381 and Y461 remain close to the azole. Y461
is predicted to be brought closer (,3.0 A ˚) than in L50S or the wild
type. By substitution of Y459 to cysteine, the azole proximity at that
position widens when triadimaenol and tebuconazole are tested (,3
to ,3.5 A ˚ and ,3t o,4.5 A ˚ respectively).
Our modelling of the Y459D substitution shows that V136 and
Y137 are withdrawn from the azole binding pocket (.4.5 A ˚ from
all docked azoles) whilst I381 is brought closer to bound triadimenol
(,3A ˚) and tebuconazole (,4.5 A ˚).
In contrast the G460D substitution shows that azoles maintain
close contact with both Y137 and Y459, however, V136 is removed
from interaction range (.4.5 A ˚). The mutated D460 residue itself is
pushed into close proximity with triadimenol, tebuconazole and
epoxiconazole (,3A ˚).
With the Y461H substitution, the most notable difference is at
the site of the mutated residue where the azole interaction with
Y461 is lost due to its change to histidine. Close proximity is
maintained between triadimenol and I381, indeed markedly closer
proximity (,3.0 A ˚ compared to ,4.5 A ˚) than for the wild type
(table S1). The inclusion of Y461H in L50S Y461H results in
residue Y123 being closer to all the docked azoles (,3A ˚) whilst
Y137 and Y459 also remain close.
L50S Y461S unsurprisingly provides a similar profile to L50S
Y461H - since serine has a smaller side chain than tyrosine, S461
is further from the tested azoles than Y461 .4.5 A ˚ for all docked
azoles). However, unlike Y461H, Y137 is withdrawn from the
azole binding region (.4.5 A ˚ from all docked azoles).
In summary, substitutions at positions 459–461 cause azole
resistance by moving residues V136 and or Y137 further from the
docked azoles, whereas the biggest impact on azole binding of
alteration at Y461 is likely to be due to the loss of the tyrosine
residue. An inference from our structural modelling is that the
agricultural azoles impose uniformly intense selective pressure at
residues between 459–461 forcing the organism toward the
adoption of an evolutionary strategy of more drastic deletion
rather than single substitutions in that region. This idea is
supported by the fact that DY459/G460 is present in the most
prevalent genotypes recently observed.
L50S V136A Y461H
V136A has not been found alone in M. graminicola. Similar to
I381V, when introduced alone and expressed in yeast it is lethal
and can be partially rescued by combining with Y459–Y461.
However, L50S V136A Y461H is a quite common variant that
causes resistance to prochloraz and it has been postulated that the
V136A substitution has been selected by the use of this imidazole
[4]. Although V136 is not within 4.5 A ˚ of prochloraz in any of our
mutants, our model agrees with this finding. Rather than
prochloraz resistance being directly via a change in the interacting
residue it is proposed that a conformational change results in Y137
and Y123 moving further from docked prochloraz that reduces
affinity.
The haem cavity volume of the natural variant, L50S V136A
Y461H, is only slightly increased to 1971 A ˚ 3 but more residues are
within 3 A ˚ of docked azoles than in the wild type. In particular,
Y137 and residue 461 are closer to all docked azoles, though for
Modelling Resistance in Mycosphaerella graminicola
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e20973prochloraz, Y137 is more than 4 A ˚ away. However, V136
proximity with triadimenol, tebuconazole and epoxiconazole is
lost. This variant causes resistance to prochloraz, far greater than
with Y461H alone. Compared to L50S Y461H, the main
difference between the two model structures is that I381 is about
1A ˚ further away in L50S V136A Y461H.
V136 is calculated as being closer than 4.5 A ˚ to the docked
azole in 15 of our 56 azole docking models, but not for prochloraz
binding (table S1). In L50S V136A Y461H, residues 459–461 are
closer to the docked azoles than in L50S Y461H.
With L50S V136A S188N DY459/G460 N513K, the haem
cavity volume is increased to 4355 A ˚ 3 causing a great reduction in
the number of residues within 3 A ˚ of docked azoles (table 2). K148
is within 3 A ˚ of tebuconazole, but further away (3.5–4.5 A ˚) from
the other azoles, which correlates with the observed sensitivity to
tebuconazole and conversely the observed resistance to epoxico-
nazole and prochloraz (table 3, figure 2C).
Inclusion of A379G
The inclusion of A379G in L50S S188N A379G I381V
DY459/G460 N513K decreases the cavity volume only slightly
to 5060 A ˚ 3 from 5204 A ˚ 3 (compared to L50S S188N I381V
DY459/G460 N513K, table 2). In this variant, Y137 is around
4A ˚ from epoxiconazole and tebuconazole (figure 2D), which gives
some scope for resistance with only the weakest form of H-bond
being possible. Indeed, both V136 and Y137 are within interaction
range of triadimenol, tebuconazole (figure 2D) and epoxiconazole,
but the conspicuous proximity of V381 to prochloraz alone is
repeated. V381 is around 2 A ˚ closer to prochloraz than the other
azoles (figure 2D). Stammler et al., (2008) [7] have found that this
construct is highly resistant against epoxiconazole and tebucona-
zole, but sensitive to prochloraz (table 3). It is interesting that the
incorporation of the A379G alteration has little impact upon the
binding capacity of the nearby 381 position (table S1), which can
be associated with interaction with prochloraz and consequent
sensitivity (table 3). The more compact structure of the valine side
chain might allow richer hydrophobic interactions with prochloraz
than the wild type isoleucine side chain accounting for the
sensitivity seen to prochloraz in this strain.
The presence of I381V in combination with other alterations
increases following the introduction of tebuconazole and decreases
after prochloraz, with no difference following epoxiconazole [4].
This sensitivity to prochloraz correlates with proximity to Y123
and particularly, V381. These findings support a notable role for
Y123 and V381 in maintaining sensitivity to prochloraz, and
suggest that despite their proximity, K133 and V136 are not
important in the interactions with triadimenol, tebuconazole and
epoxiconazole.
Recent strains and compensatory sensitivity for
tebuconazole and prochloraz
In the recent isolates, it is interesting to note that the I381V and
A379G alterations increase resistance factors to tebuconazole but
lower them for the imidazole prochloraz, whereas the V136A
alteration increased resistance to prochloraz [4,6,7]. It appears
therefore that recent alterations serve to convey resistance to one
of either tebuconazole or prochloraz, which is compensated by
sensitivity to the other. This suggests that continued administration
of combinations of azoles is feasible, providing that alterations are
restricted to combinations of the currently altered residue set.
The final column of table 3 provides a summary of the main
structural mechanisms underlying the resistance profiles observed
for the main resistance variants. Three distinct mechanisms
emerge, namely obstruction of binding or loss of interaction due to
the replacement of a specific residue; constriction of the binding
cavity by incorporation of the I381V alteration, resulting in the
cavity being inaccessible to larger azoles such as tebuconazole;
extensive increase in the volume of the binding cavity, leading to
isolation of the azole from the key interacting residues.
Alterations at other sites
A consistent feature of all the models of azole docking in this
study is the proximity of A311. It is the only residue predicted to
be closer than 4.5 A ˚ to epoxiconazole, triadimenol, tebuconazole
or prochloraz. The equivalent residue has previously been
identified in M. fijiensis as being mutated (A313G) though a link
to azole resistance could not be confirmed [26]. An alignment of
M. graminicola and M. fijiensis CYP51 sequences with Mycobacterium
tuberculosis reveals that the residue lies in the substrate signal
recognition sequence 4 (SRS4) and is also located within the I helix
[26]. Substitutions at this residue (A311G) have also been
identified in M. graminicola, and indeed used to be more common
(Fraaije et al., unpublished). A mutation affecting A311 is likely to
further reduce DMI sensitivity. The modelling also implicates the
neighbouring residue G312, though to a lesser extent (table S2),
and the G312A substitution has also been found previously. D134
is a residue in close proximity to bound triadimenol and
epoxiconazole. Interestingly the D134G substitution used to be
quite rare but now appears on the increase (Cools et al.,
unpublished). This illustrates the capacity of the modelling
approach to not only rationalise the effects of alterations that
have been characterised in the laboratory but also to identify other
residues that may susceptible to alteration in the past or in the
future and to test theoretical combinations in a predictive manner.
Conclusion
We have modelled the Mycosphaerella graminicola CYP51 enzyme
along with 13 altered sequences containing one or a combination
of amino acid alterations which have been associated with azole
resistance. The multi-homologue models were generated in a
wholly automated fashion, blind of prior functional inference and
unbiased by homologue selection. The structural models support
observations of resistance in field populations indicating that we
have created a robust model which may be used for prediction of
resistance to azoles and possible new mutations that may arise.
Our molecular modelling provides a structural rationale for the
emergence of azole resistance in M. graminicola and suggests an
element of compensationbetweenatomicrearrangement and cavity
extension in the later variants has occurred in the evolutionary
response of MgCYP51 to different fungicide exposures. Extending
the volume of the haem cavity while limiting structural rearrange-
ment would appear to be a feasible evolutionary solution that allows
the accommodation of the larger azole molecules without their
engagement in interaction, while limiting rearrangement of specific
side chains important for the general function of the enzyme that is
essential for growth.
Ourmolecular modelling ofM. graminicola CYP51 anditsvariants
provides a robust structure-function rationale for the binding of
azoles including the importance of Y137 in the binding interactions
and valuable insights of mechanisms conferring resistance. Exam-
ination of the wild type binding pocket implicates several residues in
close proximity to the positions of the bound azole molecules that
are subject to alteration, presenting a picture of the various ligands
being spatially constrained by specific regions bordering the pocket
that become the focus of genetic mutation events and those
following mutations result in subsequent resistance to that group of
related compounds. The most striking of these is the previously
structurally uncharacterised 459–461 region, which is the focus of
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at 459–460 in various resistant strains. In structural terms, the
deletion is strikingly effective, resulting in the removal of the entire
beta turn section from the vicinity of the binding pocket. The
models account for several observed functional effects of specific
mutations, including the loss of triadimenol sensitivity in isolates
possessing the Y137F variant, the lower sensitivity to tebuconazole
of I381V variants, increased resistance to prochloraz of V136A
variants together with sensitivity to triadimenol and tebuconazole;
and finally, resistance to tebuconazole and decreased sensitivity to
epoxiconazole of the A379G I381V DY459/G460 combination
coupled to sensitivity to prochloraz.
We provide detailed descriptions for how different combinations
of mutations affect binding of four different azole fungicides based
on molecular models of CYP51. All these findings support the idea
that the different binding specificities of different azoles to
particular CYP51 variants has contributed to observed amount
of polymorphism in the CYP51 gene, as a result of the mosaic of
different fungicides that have been applied in wheat fields of
Europe.
The structure – function relationships underpinning the
observation that resistance of new combinations of mutations to
new azole fungicides may increase sensitivity to older azole
fungicides might inform effective rotation of fungicides or could be
exploited to create new fungicide mixtures.
The measurement of the volume of the haem cavity was a useful
metric for assessment of the scope for general resistance to this
group of compounds by virtue of their accommodation without the
potential for key binding interactions. It appears that this
combination of methods provides the basis to a reliable in silico
predictive approach for assessing the probability of particular
variants exhibiting resistance to particular azole fungicides that
would be of value in predicting and managing the use of fungicides
in the control of this important wheat pathogen. This approach to
understanding binding of azoles can be used as a screen to identify
new fungicidal compounds and also to predict which azole classes
will be affected by any particular combination of CYP51
mutations.
In terms of studying protein evolution more generally, our
analyses have provided much insight into the role of specific amino
acids in binding azoles in M. graminicola, and how conformational
changes brought about by the alteration of particular residues,
often proximal to the ligand, can result in modified binding
capacity of other key residues. In doing so, we have established a
promising in silico protocol for the assessment of alterations and
their effects in proteins where evolutionary stress is introduced by
the extensive application of a closely related class of agents
targeting a specific protein binding domain.
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